Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adaptimmune Therapeutics ( (ADAP) ) just unveiled an update.
On July 31, 2025, Adaptimmune Therapeutics completed a significant transaction involving the sale of its cell therapy assets to USWM CT, LLC, receiving $55 million and potential future milestone payments. This transaction also allowed Adaptimmune to settle its $29.1 million debt with Hercules Capital, thereby improving its financial position and potentially impacting its future operations and market strategy.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Spark’s Take on ADAP Stock
According to Spark, TipRanks’ AI Analyst, ADAP is a Neutral.
Adaptimmune Therapeutics’ score is primarily impacted by its weak financial performance, highlighted by significant losses, negative equity, and cash flow challenges. The technical analysis also points to bearish sentiment. While there are positive developments in operations and potential restructuring benefits, ongoing financial risks and strategic uncertainties weigh heavily on the overall score.
To see Spark’s full report on ADAP stock, click here.
More about Adaptimmune Therapeutics
Adaptimmune Therapeutics is a company in the biotechnology industry, focusing on the development of cell therapies. Its primary products include TECELRA, lete-cel, afami-cel, and uza-cel cell therapies, with a market focus on innovative cancer treatments.
Average Trading Volume: 4,765,047
Technical Sentiment Signal: Sell
Current Market Cap: $27.05M
Find detailed analytics on ADAP stock on TipRanks’ Stock Analysis page.